1. < Home

dosimetry

Radiopharmaceutical Therapy-Linked Tumor Resistance: Immune Evasion, Nonimmune Mechanisms, and Immunometabolic Vulnerabilities

Abt ER, Radu CG, Czernin J, Mona CE. Radiopharmaceutical Therapy-Linked Tumor Resistance: Immune Evasion, Nonimmune Mechanisms, and Immunometabolic Vulnerabilities. J Nucl Med. 2026 Sep 11;67(Suppl[...]

By afschroeder • September 12, 2026
Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial

Ells Z, Meyer C, Kimura K, Wilhalme H, Cao M, Ludwig VB, Unterrainer LM, Sennung D, Nabong R, Felix C, Valle LF, Daley A, Czernin[...]

By afschroeder • April 3, 2026
Dosimetry of [177Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis

Ells Z, Grogan TR, Czernin J, Dahlbom M, Calais J. Dosimetry of [177Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and[...]

By sjmartinez • July 4, 2024